Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HHAT | Q5VTY9 | 2/20 | 0.41 |
| ▸ | CCKBR | P32239 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3242167 | 1.00 | POLB (0.43) | POLBTP53ALDH1A1KDM4EHTT | |
| SCHEMBL30794386 | 0.89 | TP53 (0.45) | POLBTP53ALDH1A1HTTMEN1 | |
| SCHEMBL3242926 | 0.89 | TP53 (0.45) | POLBTP53ALDH1A1HTTMEN1 | |
| SCHEMBL30795471 | 0.85 | HHAT (0.53) | MEN1KMT2AHHAT | |
| SCHEMBL3229592 | 0.85 | HHAT (0.53) | MEN1KMT2AHHAT | |
| SCHEMBL30795291 | 0.82 | TP53 (0.50) | TP53ALDH1A1HTTMEN1KMT2A | |
| SCHEMBL3242955 | 0.82 | TP53 (0.50) | TP53ALDH1A1HTTMEN1KMT2A | |
| SCHEMBL3238924 | 0.82 | HHAT (0.43) | ALDH1A1KDM4EHTTHHAT | |
| SCHEMBL30794736 | 0.82 | LMNA (0.46) | TP53ALDH1A1SMN1; SMN2KMT2AHHAT | |
| SCHEMBL30796399 | 0.82 | HHAT (0.43) | ALDH1A1KDM4EHTTHHAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| EP-4580679-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | Biohaven Therapeutics Ltd. (VG) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |